메뉴 건너뛰기




Volumn 44, Issue 3, 2013, Pages 313-317

Oxaliplatin plus 5-fluorouracil and folinic acid (off) in gemcitabine-pretreated advanced pancreatic cancer: A phase ii study

Author keywords

Locally advanced pancreatic cancer; Oxaliplatin; Oxaliplatin plus 5 fluorouracil and folinic acid; Pretreated pancreatic cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN;

EID: 84883255795     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-013-9495-5     Document Type: Article
Times cited : (10)

References (24)
  • 1
    • 0013401756 scopus 로고    scopus 로고
    • National Cancer Institute based on November 2011 SEER data submission, posted to the SEER web site, April 2012
    • National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets. 2009. http://seer.cancer.gov/csr/1975-2009-pops09, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
    • (2009) Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets
  • 2
    • 33847638137 scopus 로고    scopus 로고
    • Estimates of the cancer incidence and mortality in Europe in 2006
    • 17287242 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D
    • Ferlay J, Autier P, Boniol M, Heanue M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-92.
    • (2007) Ann Oncol , vol.18 , pp. 581-592
    • Ferlay, J.1    Autier, P.2    Boniol, M.3    Heanue, M.4
  • 3
    • 8244254377 scopus 로고    scopus 로고
    • Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    • 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D
    • Burris 3rd HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
    • (1997) J Clin Oncol , vol.15 , pp. 2403-2413
    • Burris III, H.A.1    Moore, M.J.2    Andersen, J.3
  • 4
    • 14844320515 scopus 로고    scopus 로고
    • Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: A multicenter phase II study
    • Hellenic Oncology Research Group et al. 10.1081/CNV-46502
    • Androulakis N, Syrigosk, Polyzos A, Hellenic Oncology Research Group, et al. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest. 2005;93:9-12.
    • (2005) Cancer Invest , vol.93 , pp. 9-12
    • Androulakis, N.1    Syrigosk2    Polyzos, A.3
  • 5
    • 0043132277 scopus 로고    scopus 로고
    • Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer
    • 12860947 10.1200/JCO.2003.02.071 1:CAS:528:DC%2BD2cXptlCktLc%3D
    • Hochster H, Chachoua A, Speyer J, et al. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol. 2003;21(14):2703-7.
    • (2003) J Clin Oncol , vol.21 , Issue.14 , pp. 2703-2707
    • Hochster, H.1    Chachoua, A.2    Speyer, J.3
  • 6
    • 0141959357 scopus 로고    scopus 로고
    • Weekly oxaliplatin, bolus 5-FU and LV as first line treatment of metastatic colorectal cancer: Preliminary results
    • Guarneri D, Venturino A, Addamo G. Weekly oxaliplatin, bolus 5-FU and LV as first line treatment of metastatic colorectal cancer: preliminary results. Ann Oncol. 2002;13 Suppl 5:87.
    • (2002) Ann Oncol , vol.13 , Issue.SUPPL. 5 , pp. 87
    • Guarneri, D.1    Venturino, A.2    Addamo, G.3
  • 7
    • 0037093207 scopus 로고    scopus 로고
    • Bolus fluorouracil and leucovorin with oxaliplatin as first line treatment in metastatic colorectal cancer
    • 12011134 10.1200/JCO.2002.08.144 1:CAS:528:DC%2BD38XksFaku74%3D
    • Ravaioli A, Marangolo M, Pasqiuni E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first line treatment in metastatic colorectal cancer. J Clin Oncol. 2002;20(10):2545-50.
    • (2002) J Clin Oncol , vol.20 , Issue.10 , pp. 2545-2550
    • Ravaioli, A.1    Marangolo, M.2    Pasqiuni, E.3
  • 8
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)
    • 10.1016/j.ejca.2008.10.026
    • Eisenhaurer EA, Therasse P, Borgaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhaurer, E.A.1    Therasse, P.2    Borgaerts, J.3
  • 9
    • 10744228140 scopus 로고    scopus 로고
    • CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
    • 12903007 10.1016/S1053-4296(03)00031-6
    • Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-81.
    • (2003) Semin Radiat Oncol , vol.13 , pp. 176-181
    • Trotti, A.1    Colevas, A.D.2    Setser, A.3
  • 10
    • 0036796596 scopus 로고    scopus 로고
    • Oxaliplatin: Results in colorectal carcinoma
    • 12398998 10.1016/S1040-8428(01)00192-5
    • Carrato A, Gallego J, Diaz-Rubio E. Oxaliplatin: results in colorectal carcinoma. Crit Rev Oncol Hematol. 2002;44(1):29-44.
    • (2002) Crit Rev Oncol Hematol , vol.44 , Issue.1 , pp. 29-44
    • Carrato, A.1    Gallego, J.2    Diaz-Rubio, E.3
  • 11
    • 0037068330 scopus 로고    scopus 로고
    • A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer
    • 12177775 10.1038/sj.bjc.6600467 1:CAS:528:DC%2BD38XmtVOntbY%3D
    • Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer. 2002;87(4):393-9.
    • (2002) Br J Cancer , vol.87 , Issue.4 , pp. 393-399
    • Cheeseman, S.L.1    Joel, S.P.2    Chester, J.D.3
  • 13
    • 22144433634 scopus 로고    scopus 로고
    • Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
    • 16012797 10.1007/s10637-005-1446-y 1:CAS:528:DC%2BD2MXmtVymtb4%3D
    • Tsavaris N, Kosmas C, Skopelitis H, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs. 2005;23:369-75.
    • (2005) Invest New Drugs , vol.23 , pp. 369-375
    • Tsavaris, N.1    Kosmas, C.2    Skopelitis, H.3
  • 14
    • 67650275306 scopus 로고    scopus 로고
    • A patterns-of-care study of post-progression treatment among patients with advanced pancreas cancer after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303. ASCO Annual Meeting Proceedings
    • Schrag D, Archer L, Wang X, et al. A patterns-of-care study of post-progression treatment among patients with advanced pancreas cancer after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303. ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25(Suppl pt 1):4524.
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL. , pp. 4524
    • Schrag, D.1    Archer, L.2    Wang, X.3
  • 15
    • 48949087810 scopus 로고    scopus 로고
    • A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
    • 10.1200/JCO.2008.16.7528
    • Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol. 2008;26:A4058.
    • (2008) J Clin Oncol , vol.26 , pp. 4058
    • Pelzer, U.1    Kubica, K.2    Stieler, J.3
  • 16
    • 84859089062 scopus 로고    scopus 로고
    • Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer
    • 22493549 10.3748/wjg.v18.i12.1357 1:CAS:528:DC%2BC38Xls1Gis7s%3D
    • Altwegg R, Ychou M, Guillaumon V, et al. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol. 2012;18(12):1357-64.
    • (2012) World J Gastroenterol , vol.18 , Issue.12 , pp. 1357-1364
    • Altwegg, R.1    Ychou, M.2    Guillaumon, V.3
  • 17
    • 8344288331 scopus 로고    scopus 로고
    • Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer
    • 15539911 10.1159/000080993 1:CAS:528:DC%2BD2cXpslWit70%3D
    • Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology. 2004;67:93-7.
    • (2004) Oncology , vol.67 , pp. 93-97
    • Cantore, M.1    Rabbi, C.2    Fiorentini, G.3
  • 18
    • 18744366016 scopus 로고    scopus 로고
    • Gemcitabine and oxaliplatin in gemcitabine-refractory advanced pancreatic cancer: A phase II study
    • Van Laethem JL, Polus M, Marechal R, et al. Gemcitabine and oxaliplatin in gemcitabine-refractory advanced pancreatic cancer: a phase II study. Proc Am Soc Clin Oncol. 2004;23:4119.
    • (2004) Proc Am Soc Clin Oncol , vol.23 , pp. 4119
    • Van Laethem, J.L.1    Polus, M.2    Marechal, R.3
  • 19
    • 19944427916 scopus 로고    scopus 로고
    • Salvage chemotherapy with mitomycin, docetaxel and irinotecan in metastatic pancreatic adenocarcinoma: A phase i and II trial
    • 15581049 10.1081/CNV-200032929 1:CAS:528:DC%2BD2cXosFSiu7Y%3D
    • Reni M, Panucci MG, Passoni P, et al. Salvage chemotherapy with mitomycin, docetaxel and irinotecan in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest. 2004;22:688-96.
    • (2004) Cancer Invest , vol.22 , pp. 688-696
    • Reni, M.1    Panucci, M.G.2    Passoni, P.3
  • 20
    • 3042524200 scopus 로고    scopus 로고
    • Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic cancer
    • 15221998 10.1002/cncr.20338 1:CAS:528:DC%2BD2cXlvFCmsr0%3D
    • Milella M, Gelibter A, Di Cosimo S, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic cancer. Cancer. 2004;101:133-8.
    • (2004) Cancer , vol.101 , pp. 133-138
    • Milella, M.1    Gelibter, A.2    Di Cosimo, S.3
  • 21
    • 63849329062 scopus 로고    scopus 로고
    • Second-line therapy in refractory pancreatic cancer. Results of a phase II study
    • 19295247 10.1159/000197769 1:CAS:528:DC%2BD1MXjtlOlsrs%3D
    • Pelzer U, Stieler J, Roll L, et al. Second-line therapy in refractory pancreatic cancer. Results of a phase II study. Onkologie. 2009;32:99-102.
    • (2009) Onkologie , vol.32 , pp. 99-102
    • Pelzer, U.1    Stieler, J.2    Roll, L.3
  • 22
    • 39549120238 scopus 로고    scopus 로고
    • The role of second-line chemotherapy for gemcitabine failure in patients with advanced pancreatic cancer
    • 18240999 10.2217/14796694.4.1.41 1:CAS:528:DC%2BD1cXhslehs7g%3D
    • Boeck S, Heinemann V. The role of second-line chemotherapy for gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol. 2008;4:41-50.
    • (2008) Future Oncol , vol.4 , pp. 41-50
    • Boeck, S.1    Heinemann, V.2
  • 23
    • 34548241874 scopus 로고    scopus 로고
    • Shh signaling and pancreatic cancer: Implications for therapy?
    • 17611415 10.4161/cc.6.13.4467 1:CAS:528:DC%2BD2sXhtFWlsrzK
    • Morton JP, Lewis BC. Shh signaling and pancreatic cancer: implications for therapy? Cell Cycle. 2007;6:1553-7.
    • (2007) Cell Cycle , vol.6 , pp. 1553-1557
    • Morton, J.P.1    Lewis, B.C.2
  • 24
    • 74949135901 scopus 로고    scopus 로고
    • Targeting Notch signaling in pancreatic cancer patients - Rationale for new therapy
    • Mysliviec P, Boucher MJ. Targeting Notch signaling in pancreatic cancer patients - rationale for new therapy. Adv Med Sci. 2009;54:136-42.
    • (2009) Adv Med Sci , vol.54 , pp. 136-142
    • Mysliviec, P.1    Boucher, M.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.